Buy Or Sell Opportunity • Jun 19
Now 20% undervalued Over the last 90 days, the stock has risen 7.5% to ₩7,700. The fair value is estimated to be ₩9,646, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has grown by 16%. Buy Or Sell Opportunity • May 26
Now 33% overvalued after recent price rise Over the last 90 days, the stock has risen 62% to ₩13,320. The fair value is estimated to be ₩9,981, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has grown by 16%. New Risk • May 24
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 20% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. This is currently the only risk that has been identified for the company. Valuation Update With 7 Day Price Move • May 08
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩13,180, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 201% over the past three years. Buy Or Sell Opportunity • Apr 24
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 99% to ₩11,060. The fair value is estimated to be ₩9,119, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 22% in a year. Earnings are forecast to grow by 53% in the next year. New Risk • Apr 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (74% net debt to equity). Share price has been volatile over the past 3 months (13% average weekly change). Valuation Update With 7 Day Price Move • Apr 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩8,130, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Chemicals industry in South Korea. Total returns to shareholders of 124% over the past three years. Buy Or Sell Opportunity • Apr 07
Now 22% undervalued Over the last 90 days, the stock has risen 16% to ₩6,800. The fair value is estimated to be ₩8,747, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 22% in a year. Earnings are forecast to grow by 53% in the next year. Buy Or Sell Opportunity • Mar 23
Now 21% undervalued Over the last 90 days, the stock has risen 6.4% to ₩6,800. The fair value is estimated to be ₩8,605, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.2% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 22% in a year. Earnings are forecast to grow by 53% in the next year. Reported Earnings • Mar 21
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: EPS: ₩400 (up from ₩243 in FY 2024). Revenue: ₩153.2b (up 22% from FY 2024). Net income: ₩13.2b (up 63% from FY 2024). Profit margin: 8.6% (up from 6.4% in FY 2024). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates by 5.0%. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has increased by 27% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Mar 04
Samyoung Co.,Ltd., Annual General Meeting, Mar 31, 2026 Samyoung Co.,Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 565, gyeongin-ro, guro-gu, seoul South Korea Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩9,170, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 207% over the past three years. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩6,530, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 133% over the past three years. Upcoming Dividend • Dec 22
Upcoming dividend of ₩20.00 per share Eligible shareholders must have bought the stock before 29 December 2025. Payment date: 28 April 2026. Payout ratio is a comfortable 6.5% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of South Korean dividend payers (3.6%). Lower than average of industry peers (1.3%). Valuation Update With 7 Day Price Move • Dec 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩7,460, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 186% over the past three years. Valuation Update With 7 Day Price Move • Nov 14
Investor sentiment improves as stock rises 30% After last week's 30% share price gain to ₩6,000, the stock trades at a trailing P/E ratio of 28x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 125% over the past three years. New Risk • Nov 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Profit margins are more than 30% lower than last year (5.5% net profit margin). Declared Dividend • Nov 08
Dividend of ₩20.00 announced Dividend of ₩20.00 is the same as last year. Ex-date: 29th December 2025 Payment date: 28th April 2026 Dividend yield will be 0.4%, which is lower than the industry average of 1.7%. Aankondiging • Nov 07
Samyoung Co.,Ltd. announces Annual dividend, payable on April 28, 2026 Samyoung Co.,Ltd. announced Annual dividend of KRW 20.0000 per share payable on April 28, 2026, ex-date on December 29, 2025 and record date on December 31, 2025. Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₩5,310, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 117% over the past three years. New Risk • Aug 19
New major risk - Financial position The company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (currently running at an operating cash loss). Minor Risk Profit margins are more than 30% lower than last year (5.5% net profit margin). Reported Earnings • Aug 19
Second quarter 2025 earnings released: EPS: ₩43.00 (vs ₩101 in 2Q 2024) Second quarter 2025 results: EPS: ₩43.00 (down from ₩101 in 2Q 2024). Revenue: ₩33.4b (flat on 2Q 2024). Net income: ₩1.42b (down 58% from 2Q 2024). Profit margin: 4.3% (down from 10% in 2Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Aankondiging • Jun 19
Samyoung Co.,Ltd. (KOSE:A003720) agreed to acquire 99.63% stake in CASCO Co., Ltd. from PTclover Co., Ltd. for KRW 35.5 billion. Samyoung Co.,Ltd. (KOSE:A003720) agreed to acquire 99.63% stake in CASCO Co., Ltd. from PTclover Co., Ltd. for KRW 35.5 billion on June 18, 2025. A cash consideration of KRW 35.5 billion will be paid by Samyoung Co.,Ltd. As part of consideration, KRW 35.5 billion is paid towards common equity of CASCO Co., Ltd.
The expected completion of the transaction is July 1, 2025. New Risk • Mar 27
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.4% Last year net profit margin: 11% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (6.4% net profit margin). Market cap is less than US$100m (₩131.9b market cap, or US$89.8m). Aankondiging • Mar 07
Samyoung Co.,Ltd., Annual General Meeting, Mar 28, 2025 Samyoung Co.,Ltd., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 565, gyeongin-ro, guro-gu, seoul South Korea Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩4,835, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total returns to shareholders of 43% over the past three years. Valuation Update With 7 Day Price Move • Jan 20
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₩4,325, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 7x in the Chemicals industry in South Korea. Total returns to shareholders of 33% over the past three years. Upcoming Dividend • Dec 20
Upcoming dividend of ₩20.00 per share Eligible shareholders must have bought the stock before 27 December 2024. Payment date: 28 April 2025. Payout ratio is a comfortable 4.6% and this is well supported by cash flows. Trailing yield: 0.5%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (2.2%). Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩3,750, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 7x in the Chemicals industry in South Korea. Total returns to shareholders of 31% over the past three years. Reported Earnings • Nov 20
Third quarter 2024 earnings released: EPS: ₩51.00 (vs ₩52.65 in 3Q 2023) Third quarter 2024 results: EPS: ₩51.00 (down from ₩52.65 in 3Q 2023). Revenue: ₩31.2b (up 5.4% from 3Q 2023). Net income: ₩1.69b (down 4.2% from 3Q 2023). Profit margin: 5.4% (down from 6.0% in 3Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 60% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. New Risk • Nov 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩137.8b market cap, or US$99.9m). Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩3,080, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 9x in the Chemicals industry in South Korea. Total loss to shareholders of 8.6% over the past three years. New Risk • Mar 19
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩132.8b (US$99.2m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks High level of debt (84% net debt to equity). Profit margins are more than 30% lower than last year (2.2% net profit margin). Market cap is less than US$100m (₩132.8b market cap, or US$99.2m). New Risk • Jan 25
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩132.7b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks High level of debt (84% net debt to equity). Profit margins are more than 30% lower than last year (2.2% net profit margin). Market cap is less than US$100m (₩132.7b market cap, or US$99.4m). New Risk • Nov 25
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 2.2% Last year net profit margin: 3.2% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (84% net debt to equity). Profit margins are more than 30% lower than last year (2.2% net profit margin). Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to ₩4,930, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 172% over the past three years. Reported Earnings • Aug 20
Second quarter 2023 earnings released: EPS: ₩37.00 (vs ₩6.00 in 2Q 2022) Second quarter 2023 results: EPS: ₩37.00 (up from ₩6.00 in 2Q 2022). Revenue: ₩33.6b (down 6.4% from 2Q 2022). Net income: ₩1.25b (up ₩1.05b from 2Q 2022). Profit margin: 3.7% (up from 0.6% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 70% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. New Risk • Aug 08
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₩130.2b (US$99.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks High level of debt (86% net debt to equity). Profit margins are more than 30% lower than last year (2.0% net profit margin). Market cap is less than US$100m (₩130.2b market cap, or US$99.5m). Valuation Update With 7 Day Price Move • Jul 24
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₩4,840, the stock trades at a forward P/E ratio of 20x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 240% over the past three years. Reported Earnings • May 21
First quarter 2023 earnings released: EPS: ₩44.00 (vs ₩40.00 in 1Q 2022) First quarter 2023 results: EPS: ₩44.00 (up from ₩40.00 in 1Q 2022). Revenue: ₩34.4b (down 12% from 1Q 2022). Net income: ₩1.49b (up 11% from 1Q 2022). Profit margin: 4.3% (up from 3.5% in 1Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 51% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • May 04
Investor sentiment improves as stock rises 33% After last week's 33% share price gain to ₩5,380, the stock trades at a trailing P/E ratio of 67.7x. Average trailing P/E is 15x in the Chemicals industry in South Korea. Total returns to shareholders of 350% over the past three years. Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩3,720, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 331% over the past three years. Valuation Update With 7 Day Price Move • Feb 22
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩3,120, the stock trades at a trailing P/E ratio of 21.8x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 179% over the past three years. Valuation Update With 7 Day Price Move • Sep 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₩2,415, the stock trades at a trailing P/E ratio of 19.1x. Average trailing P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 122% over the past three years. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment improved over the past week After last week's 29% share price gain to ₩3,300, the stock trades at a trailing P/E ratio of 25x. Average trailing P/E is 14x in the Chemicals industry in South Korea. Total returns to shareholders of 217% over the past three years. Reported Earnings • Mar 31
Full year 2020 earnings released: EPS ₩6.00 (vs ₩59.00 loss in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ₩117.7b (up 5.9% from FY 2019). Net income: ₩214.7m (up ₩2.23b from FY 2019). Profit margin: 0.2% (up from net loss in FY 2019). Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has only increased by 39% per year, which means it is significantly lagging earnings growth. Aankondiging • Mar 06
SamYoung Chemical Co.,Ltd, Annual General Meeting, Mar 26, 2021 SamYoung Chemical Co.,Ltd, Annual General Meeting, Mar 26, 2021, at 10:00 Korea Standard Time. Is New 90 Day High Low • Jan 07
New 90-day high: ₩3,020 The company is up 30% from its price of ₩2,325 on 08 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period. Is New 90 Day High Low • Dec 11
New 90-day high: ₩2,560 The company is up 31% from its price of ₩1,950 on 11 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 14% over the same period. Is New 90 Day High Low • Oct 12
New 90-day high: ₩2,465 The company is up 108% from its price of ₩1,185 on 14 July 2020. The South Korean market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 30% over the same period. Is New 90 Day High Low • Sep 18
New 90-day high: ₩2,330 The company is up 88% from its price of ₩1,240 on 19 June 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 32% over the same period. 
